Batavia Biosciences Announces Release of GMP Production  Facility 

This strategic move represents a significant leap in Batavia's capabilities to deliver clinical manufacturing of viral vaccines and viral vectors. 
Batavia Biosciences - Favicon

Leiden, November 21, 2023 – Batavia Biosciences, a Center of Excellence Contract Development and Manufacturing Organization (CDMO), proudly announces the release of ‘Amalia,’ a GMP-ready manufacturing facility in Bilthoven, Netherlands. This strategic move represents a significant leap in Batavia’s capabilities to deliver clinical manufacturing of viral vaccines and viral vectors. 

Menzo Havenga, CEO Batavia Biosciences, says: “The release of this facility is a significant achievement for our company. It supports Batavia Biosciences’ mission of being a center of excellence able to support customers’ vital efforts to bring essential medical countermeasures from the lab to the patients who need them most. This facility is critical to increasing clinical manufacturing capacity to align with market needs and support epidemic preparedness.”   

Accommodated within a space leased from Bilthoven Biologicals, ‘Amalia’ is Batavia Biosciences’ response to the growing demand for high-quality clinical manufacturing and epidemic preparedness. The facility houses advanced equipment and complying with stringent quality standards, making it a cornerstone for innovation in viral vector and vaccine development and production. 

Amalia maintains up to Grade B cleanroom standards to ensure sterile and safe production environments. Equipped with two upstream suites, the facility is designed for parallel manufacturing of viral vectors and vaccines at volumes reaching 200 liters. Leveraging advanced single-use technologies suitable for suspension and adherent cells, the facility operates under strict Biosafety Level 2 (BSL-2) protocols, enabling the safe handling of pathogens such as Measles, Herpes Simplex, and Influenza. 

This endeavor is part of a larger expansion strategy supported by active investment from CJ CheilJedang, aligning with Batavia Biosciences’ vision to establish Batavia Biomanufacturing. The Amalia facility is a steppingstone towards the ambitious launch of the more extensive, state-of-the-art facility in Leiden. Once operational, the Leiden site is expected not only to complement but eventually supersede Amalia with a daily production capacity planned to reach an impressive 576,000 vials. 

Amalia’s release will enable Batavia Biosciences to consolidate its position further, offering end-to-end solutions to bring therapies from scientists to patients. 

For press inquiries and more information, stay tuned for upcoming announcements from Batavia Biosciences. 

About Batavia Biosciences 

Batavia Biosciences significantly contributes to ease human suffering from infectious diseases, cancer, and rare diseases by leveraging our innovative technologies and in-depth know-how. We do this for viral vaccines and cell and gene therapies at all stages of the development trajectory, from the transition into early clinical studies, to navigating late-stage clinical development and entering commercial manufacturing at higher speed, reduced costs, and with increased success. The company operates state-of-the-art development and manufacturing facilities in Europe and the US and, as part of the CJ CheilJedang global family, is building a strong position in global health with its strategic partners worldwide.  

Related

New Test for Rapid and Low-cost Quality Control for Polio Vaccines

Batavia Biosciences has developed a qPCR method that can specifically detect mutations that can accumulate in poliovirus strains during vaccine production. The test demonstrates a sensitivity level highly comparable to current best practices. The novel test has been accepted for publication in the international, peer-reviewed prestigious Vaccine journal.

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression